



Tom McKillop
AGM

Headline results FY 04

| | 2004 \$m | 2003 \$m | Actual growth | CER growth |
|------------------|-------------|-------------|------------------|---------------|
| Sales | 21,426 | 18,849 | +14% | +9% |
| Operating profit | 4,770 | 4,111 | +16% | +15% |
| EPS (pre-excep) | \$2.11 | \$1.78 | +19% | +18% |
| EPS | \$2.28 | \$1.78 | +28% | +27% |
| Dividends | \$0.94 | \$0.795 | | |



Key growth products

| | 2004 Sales \$m | Growth (CER) |
|-----------|-------------------|-----------------|
| Nexium | 3,883 | +15% |
| Seroquel | 2,027 | +33% |
| Arimidex | 811 | +48% |
| Casodex | 1012 | +11% |
| Symbicort | 797 | +32% |
| Crestor | 908 | n/m |
| Iressa | 389 | +65% |


AstraZeneca 

Headline results 1Q 05

| | 2005 \$m | 2004 \$m | Actual growth | CER growth |
|------------------|-------------|-------------|------------------|---------------|
| Sales | 5,743 | 5,074 | +13% | +9% |
| Operating profit | 1,453 | 1,052 | +38% | +34% |
| EPS | \$0.63 | \$0.47 | +34% | +33% |

AstraZeneca 

Share price performance




AstraZeneca 

 **exanta**

 **IRESSA**


CRESTOR

AstraZeneca 





Tom McKillop

AGM